Dr. Jayendra D. Patel M.D.

Recommended Articles

• The Promising Future of Gene Therapy and Lymphoma

  Non-Hodgkin lymphoma affects over 700,000 people in America alone. Though current treatments are moderately effective, especially for aggressive forms of the disease, more can be done to help people impacted by NHL. Researchers are doing just that by working to develop new, innovative treatment for...

• New Diagnostic Tool Approved for Lymphoma

  A new diagnostic tool has been approved by the U.S. Food and Drug Administration (FDA) to help researchers identify leukemia and lymphoma cells by using a technique known as flow cytometry. A flow cytometry test for non-Hodgkin’s lymphoma (NHL) can help determine whether normal or abnormal DNA is...

• Genetic Advancements in Lymphoma Treatment

  Cancers are a huge focus for research. Millions of dollars every year are funneled into funding research that could improve treatment methods or find cures for cancer, including blood cancers. Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL) accounting...

• Teen with Hodgkin Lymphoma Skates with Her Hero, Mario Lemieux

  Lillian Tarasiewicz was diagnosed with stage 3B Hodgkin lymphoma in October of 2015. She currently resides in South Carolina, but because of her father’s Pennsylvania background, she grew up with a love for hockey and for the Pittsburgh Penguins. She always felt a special connection to Mario...

• The Blow Self-Image Can Take During Lymphoma Treatment

  Many who have endured cancer treatment experience a blow to their self image, and cease to recognize the person looking back at them in the mirror.However, it does not have to be that way! Here are some of the most common changes, and how to cope with them.Skin changesYou may begin to see your skin...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...